[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553043":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":102,"collaborators":104,"id":108,"slug":10,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":10,"enrollmentInfo":116,"targetDuration":119,"studyType":120,"phases":10,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Cardiovascular and Interventional Radiological Society of Europe","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Full cohort",null,"Cryoablation with curative-intent of bone metastases from oligometastatic or bone oligo-progressive disease.",[13],"Device: Cryoablation system",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Cryoablation system","Any cryoablation system from Boston Scientific that has received CE Mark and\u002For FDA clearance for the ablation of bone malignancies.",[9],[21],{"name":22,"affiliation":23,"role":24},"Roberto L Cazzato, Dr","Strasbourg University Hospitals, Strasbourg, France","STUDY_CHAIR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Claire E Poulet, PhD","CONTACT","+41 79 385 16 78","borealis@cirse.org",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Dhwani S. Korde, PhD","+4367762942469","borealise@cirse.org",[36,52,64,76,89],{"facility":37,"status":38,"city":39,"state":10,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Institute Bergonié","RECRUITING","Bordeaux","33076","France",{"type":43,"coordinates":44},"Point",[45,46],-0.58046,44.84124,{"lat":46,"lon":45},[49],{"name":50,"role":51,"phone":10,"phoneExt":10,"email":10},"Xavier Buy, Dr","PRINCIPAL_INVESTIGATOR",{"facility":53,"status":38,"city":54,"state":10,"zip":55,"country":41,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"CHRU de Strasbourg","Strasbourg","67200",{"type":43,"coordinates":57},[58,59],7.74553,48.58392,{"lat":59,"lon":58},[62],{"name":63,"role":51,"phone":10,"phoneExt":10,"email":10},"Roberto Luigi Cazzato, Dr",{"facility":65,"status":38,"city":66,"state":10,"zip":67,"country":41,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Institut Gustave Roussy","Villejuif","94805",{"type":43,"coordinates":69},[70,71],2.35992,48.7939,{"lat":71,"lon":70},[74],{"name":75,"role":51,"phone":10,"phoneExt":10,"email":10},"Frederic Deschamps, Dr",{"facility":77,"status":38,"city":78,"state":10,"zip":79,"country":80,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Hospital Universitario y Politécnico La Fe","Valencia","46026","Spain",{"type":43,"coordinates":82},[83,84],-0.37966,39.47391,{"lat":84,"lon":83},[87],{"name":88,"role":51,"phone":10,"phoneExt":10,"email":10},"Fernando Gómez Muñoz, Dr",{"facility":90,"status":38,"city":91,"state":10,"zip":92,"country":93,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"CHUV-Lausanne University Hospital","Lausanne","1011","Switzerland",{"type":43,"coordinates":95},[96,97],6.63282,46.516,{"lat":97,"lon":96},[100],{"name":101,"role":51,"phone":10,"phoneExt":10,"email":10},"Georgia Tsoumakidou, Dr",{"type":103,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[105],{"name":106,"class":107},"Boston Scientific Corporation","INDUSTRY","100553043",false,"NCT06480955","BOne Metastases REgistry for Patients Undergoing cryoAbLation With curatIve purpoSe","BOREALIS","Inclusion Criteria:\n\n* Bone metastases in patients with oligometastatic disease (\\\u003C5 bone\u002Fvisceral metastases) or bone oligo-progressive disease (visceral or osseous multi-metastatic disease stable under systemic treatment except 1-3 progressing bone metastases) from solid tumours;\n* Number of target lesions ≤ 3\n* Size of target lesion(s) \\\u003C 5 cm (largest diameter);\n* Referral to local ablative treatment by multidisciplinary tumour board (MDTB);\n* Treatment by percutaneous cryoablation with curative intent (i.e., complete tumour destruction) assessed as technically feasible by the IR in charge;\n* Procedure performed with a cryoablation system from Boston Scientific.\n\nExclusion Criteria:\n\n* \\\u003C 18 years old;\n* Incapacity or refusal to give informed consent;\n* Ongoing pregnancy;\n* Health status not compatible with the minimum meaningful follow-up period (i.e., 12 months):\n\n  * Karnofsky Performance Scale \\\u003C 60%, or\n  * Bone metastases originating from rapidly evolving tumour histologies not allowing reasonable life expectancy of at least 12 months, or\n  * Life expectancy \\\u003C 12 months\n* Infection of treatment site or systemic infection;\n* Uncorrectable coagulopathy;\n* Haematological disease (including multiple myeloma and plasmacytoma);\n* Concomitant radiation therapy or radiation therapy within 12 weeks before the planned cryoablation procedure.","ALL","18 Years",{"count":117,"type":118},50,"ESTIMATED","1 Year","OBSERVATIONAL","BOREALIS is a multicentre, prospective, observational cohort study designed to investigate the effectiveness, feasibility, safety and impact on pain and quality of life of curative-intent cryoablation for the treatment of bone metastases in patients with oligometastatic or bone oligo-progressive disease.",[123],"Bone Metastases",[125,126,127,128],"Cryoablation Oligo-progressive disease","Bone metastases","Oligometastatic Disease","Oligo-progressive disease","2025-12-23",{"date":131,"type":132},"2025-12-30","ACTUAL",{"date":134,"type":132},"2025-04-01",{"date":136,"type":118},"2028-04",{"name":5,"class":6},5]